Physician profile
Karan Gupta
NPI 1093157836
$29,261.80
in general payments reported to CMS, 2019-2025
36 companies · $3,166 in 2025
The $3,166 reported for 2025 was more than what 90% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2021: $537 · 2022: $8,915 · 2023: $8,685 · 2024: $7,848 · 2025: $3,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,403 · Food and Beverage: $8,360 · Travel and Lodging: $1,936 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,402.92 |
| Food and Beverage | $8,359.56 |
| Travel and Lodging | $1,935.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $18,982.05 | 2022-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Astrazeneca Pharmaceuticals LP | $2,908.94 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Actelion Pharmaceuticals US, INC. | $1,624.16 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Glaxosmithkline, LLC. | $971.18 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Merit Medical Systems INC | $792.67 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $769.95 | 2022-2025 | Dupixent |
| Genzyme Corporation | $565.81 | 2022-2025 | |
| Amgen INC. | $362.77 | 2022-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $362.14 | 2022-2025 | Winrevair, Verquvo |
| Boston Scientific Corporation | $341.40 | 2019-2022 | |
| Grifols USA, LLC | $263.29 | 2023-2025 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $145.49 | 2021-2025 | Camzyos, Eliquis |
| La Jolla Pharmaceutical Company | $139.38 | 2023-2025 | Giapreza, Xerava |
| Viatris Specialty LLC | $111.28 | 2025 | Yupelri |
| Electromed, INC. | $105.37 | 2022-2025 | Smartvest |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81.02 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.74 | 2024-2025 | Glassia |
| Inogen, INC. | $74.56 | 2024-2025 | |
| Harmony Biosciences LLC | $72.67 | 2021-2023 | Wakix |
| Mylan Specialty L.P. | $70.56 | 2022-2024 | Yupelri |
| Edwards Lifesciences Corporation | $56.85 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Paratek Pharmaceuticals, INC. | $42.16 | 2025 | Nuzyra |
| Novo Nordisk INC | $38.58 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $36.97 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.97 | 2021 | |
| Abiomed | $31.29 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.86 | 2025 | |
| Shionogi INC | $24.55 | 2024 | Fetroja |
| Kiniksa Pharmaceuticals International, Plc | $24.44 | 2024 | Arcalyst |
| Pfizer INC. | $23.79 | 2023 | |
| Pulmonx Corporation | $19.66 | 2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Baxter Healthcare | $19.03 | 2023 | Hillrom - Life 2000 Ventilation System |
| Inspire Medical Systems, INC. | $16.62 | 2025 | Inspire |
| Zoll Respicardia, INC. | $16.29 | 2025 | Remede System |
| Lilly USA, LLC | $15.65 | 2025 | Zepbound |
| Genentech USA, INC. | $14.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.